Lipkowitz M A
American College of Allergy, Asthma, and Immunology and Kimball Medical Center, Saint Barnabas Health Care System, Lakewood, NJ, USA.
J Allergy Clin Immunol. 1999 Feb;103(2 Pt 2):S364-72. doi: 10.1016/s0091-6749(99)70266-6.
There are few data available to assess the safety during pregnancy of agents currently used to treat asthma and allergic disorders. The American College of Allergy, Asthma, and Immunology Registry for Allergic, Asthmatic Pregnant Patients (RAAPP) was established to provide data to assess the hypothesis that the aggressive treatment of asthma and allergy in pregnant women will encourage positive outcomes for mother and baby. Currently in progress is a pilot study of 800 patients who require inhaled corticosteroids during pregnancy. The major outcome variable for the pilot study is small for gestational age, defined as a birth weight below the 10th percentile for gestational age. After evaluation of these data, the Registry will probably be opened to general enrollment of any pregnant patient with allergy and/or asthma, regardless of medication use. When completed, RAAPP will enable physicians to evaluate the safety of medications commonly used by allergists to treat allergy and asthma during pregnancy.
目前几乎没有数据可用于评估当前用于治疗哮喘和过敏性疾病的药物在孕期的安全性。美国过敏、哮喘与免疫学会的哮喘及过敏孕妇注册登记处（RAAPP）的设立，旨在提供数据以评估以下假设：积极治疗孕妇的哮喘和过敏会给母婴带来良好结局。目前正在对800名孕期需要吸入性糖皮质激素的患者进行一项试点研究。该试点研究的主要结局变量是小于胎龄儿，定义为出生体重低于同孕周第10百分位数。在对这些数据进行评估之后，该注册登记处可能会向任何患有过敏和/或哮喘的孕妇开放全面登记，无论其用药情况如何。完成后，RAAPP将使医生能够评估过敏专科医生在孕期治疗过敏和哮喘常用药物的安全性。
